| Literature DB >> 28663799 |
L Del Gigia-Aguirre1, W Sánchez-Yebra-Romera1, S García-Muñoz1, M Rodríguez-Maresca1.
Abstract
Entities:
Year: 2017 PMID: 28663799 PMCID: PMC5480822 DOI: 10.1016/j.nmni.2017.05.004
Source DB: PubMed Journal: New Microbes New Infect ISSN: 2052-2975
Susceptibility results of Vibrio harveyi
| Antibiotic | MIC (μg/mL) |
|---|---|
| Amoxicillin/clavulanate | ≤8/4 |
| Imipenem | ≤1 |
| Piperacillin/tazobactam | ≤8 |
| Ertapenem | ≤0.5 |
| Cefalotin | 16 |
| Gentamicin | 8 |
| Cefazolin | 16 |
| Tobramycin | 4 |
| Cefuroxime | 16 |
| Amikacin | 16 |
| Cefotaxime | ≤1 |
| Nalidixic acid | ≤16 |
| Ceftazidime | ≤1 |
| Ciprofloxacin | ≤0.5 |
| Cefepime | ≤1 |
| TMP/SMX | ≤2/38 |
| Aztreonam | 8 |
| Tigecycline | ≤1 |
MIC, minimum inhibitory concentration; TMP/SMX, trimethoprim/sulfamethoxazole.